What’s the current market cap for Quest Diagnostics stock?

Quest Diagnostics (DGX) has a market cap of $24bn as of July 04, 2026.

What is the P/E ratio for Quest Diagnostics stock?

The price to earnings (P/E) ratio for Quest Diagnostics (DGX) stock is 23.84 as of July 04, 2026.

Does Quest Diagnostics stock pay dividends?

Yes, the Quest Diagnostics (DGX) stock pays dividends to shareholders. As of July 04, 2026, the dividend rate is $3.26 and the yield is 1.59%. Quest Diagnostics has a payout ratio of 34.86% on a trailing twelve-month basis.

When is the next Quest Diagnostics dividend payment date?

The next Quest Diagnostics (DGX) dividend payment is scheduled for July 22, 2026.

What is the beta indicator for Quest Diagnostics?

Quest Diagnostics (DGX) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Quest Diagnostics stock | $DGX Share Price

13:30

15:10

16:45

18:25

20:00

About Quest Diagnostics

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

Ticker

$DGX

Sector

Health

Primary listing

NYSE

Employees

51,500

Headquarters

Secaucus, United States

Website

www.questdiagnostics.com

DGX Metrics

BasicAdvanced

$24bn

23.84

$9.05

0.60

$3.26

1.59%

What the Analysts think about DGX

Analyst ratings (Buy, Hold, Sell) for Quest Diagnostics stock.

Bulls say / Bears say

First quarter 2026 net revenues rose 9.2% year over year to $2.90 billion, while adjusted diluted EPS increased 13.1% to $2.50, reflecting robust organic demand and operational leverage (PR Newswire)

After beating fourth-quarter 2025 results, Quest forecast 2026 net revenues of $11.70–$11.82 billion and adjusted diluted EPS of $10.50–$10.70, both exceeding analysts’ estimates (Marketscreener)

Strategic collaborations with Fresenius Medical Care and Corewell Health enabled scaling of lab and water purity testing solutions across dialysis clinics and hospitals, diversifying revenue channels (PR Newswire)

GAAP results were reduced by $7 million in restructuring and integration charges in Q1 2026, reflecting ongoing costs of integrating strategic partnerships (NASDAQ)

Revenue per requisition fell 1.3% year-over-year in Q1 2026, indicating a shift toward lower-margin routine tests under recent partnership contracts (PR Newswire)

Coverage and reimbursement by insurance payors is complex and unpredictable, with adverse changes potentially limiting test volumes and revenue growth (SEC)

Data summarised monthly by Lightyear AI. Last updated on 27 Jun 2026.

DGX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

DGX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.